{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:39Z","timestamp":1788869259124,"version":"build-2803163510"},"reference-count":31,"publisher":"AOSIS","issue":"0","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Hyperprolactinaemia among patients on antipsychotic medications is generally overlooked due to lack of outwardly visible symptoms, patient resistance to reporting because the symptoms are perceived as shameful, or to clinician\u2019s insufficient knowledge.\n\nAim:\u00a0The study aimed to evaluate the patterns and correlates of hyperprolactinemia among patients with schizophrenia on antipsychotic medications.\n\nSetting:\u00a0The study was conducted in a psychiatric facility in Maiduguri, Northeastern Nigeria.\n\nMethods:\u00a0A total of 209 patients with schizophrenia were evaluated through a cross-sectional design and assayed for serum prolactin with ELISA Kits. Frequencies and percentages were tabulated for categorical variables. Variables with significant associations with hyperprolactinaemia on chi-square (p\u00a0&lt; 0.05) were subjected to logistic regression analysis.\n\nResults:\u00a0The prevalence of hyperprolactinaemia was 45.9% in all patients on antipsychotic medication. The prevalence because of the use of typical and atypical antipsychotics was 51.5% and 25.0%, respectively. Hyperprolactinaemia was significantly associated with typical antipsychotics (\u03b2 = 0314,\u00a0p\u00a0= 0.002), high overall drug dosage (\u03b2 = 2.340,\u00a0p\u00a0= 0.003), high-dose typical antipsychotics (\u03b2 = 3.228,\u00a0p\u00a0= 0.000), twice daily dosing frequency (\u03b2 = 2.751,\u00a0p\u00a0= 0.001) and polypharmacy (\u03b2 = 1.828,\u00a0p\u00a0= 0.0024).\n\nConclusion:\u00a0The findings support that patients on typical, high-dose antipsychotic medications and polypharmacy have a high prevalence of hyperprolactinaemia. As hyperprolactinaemia is often undetectable, screening and patient psycho-education on the significance of the signs and symptoms of hyperprolactinaemia is required for necessary clinical intervention.\n\nContribution:\u00a0The study provides evidence for the rational use of antipsychotic medications in sub-Saharan Africa.<\/jats:p>","DOI":"10.4102\/sajpsychiatry.v30i0.2133","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:28:50Z","timestamp":1706765330000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri"],"prefix":"10.4102","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-2986","authenticated-orcid":false,"given":"Falmata B.","family":"Shettima","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04nye8z78","id-type":"ROR","asserted-by":"publisher"}],"name":"Federal Neuropsychiatric Hospital Dawanau, Kano"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-0779","authenticated-orcid":false,"given":"Musa A.","family":"Wakil","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05fx5mz56","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Nigeria Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-6554","authenticated-orcid":false,"given":"Taiwo L.","family":"Sheikh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019apvn83","id-type":"ROR","asserted-by":"publisher"}],"name":"Ahmadu Bello University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-6063","authenticated-orcid":false,"given":"Mohammed","family":"Abdulaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-0524","authenticated-orcid":false,"given":"Ibrahim A.","family":"Wakawa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05fx5mz56","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Nigeria Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5844-9471","authenticated-orcid":false,"given":"Omeiza","family":"Beida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Milano W, D\u2019Acunto CW, De Rosa M, et al. Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Rev Recent Clin Trials. 2011 Jan 1;6(1):52\u201364. https:\/\/doi.org\/10.2174\/157488711793980138","DOI":"10.2174\/157488711793980138"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Dehelean L, Romosan AM, Papava I, et al. Prolactin response to antipsychotics: An inpatient study. PLoS One. 2020 Feb 4;15(2):e0228648. https:\/\/doi.org\/10.1371\/journal.pone.0228648","DOI":"10.1371\/journal.pone.0228648"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: A clinical review. Psychosomatics. 2014 Jan 1;55(1):29\u201336. https:\/\/doi.org\/10.1016\/j.psym.2013.08.008","DOI":"10.1016\/j.psym.2013.08.008"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Milano W, Colletti C, Capasso A. Hyperprolactinemia induced by antipsychotics: From diagnosis to treatment approach. Endocr Metab Immune Disord Drug Targets. 2017 Mar 1;17(1):38\u201355. https:\/\/doi.org\/10.2174\/1871530317666170424102332","DOI":"10.2174\/1871530317666170424102332"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ates MA, Tutuncu R, Oner I, et al. Relationship between plasma levels of prolactin and the severity of negative symptoms in patients with schizophrenia. Klin Psikofarmakol B. 2015 Mar 1;25(1):27\u201337. https:\/\/doi.org\/10.5455\/bcp.20141212113905","DOI":"10.5455\/bcp.20141212113905"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000 Apr 1;157(4):514\u2013520. https:\/\/doi.org\/10.1176\/appi.ajp.157.4.514","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs. 2014 May;28(5):421\u2013453. https:\/\/doi.org\/10.1007\/s40263-014-0157-3","DOI":"10.1007\/s40263-014-0157-3"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Lally J, Ajnakina O, Stubbs B, et al. Hyperprolactinaemia in first episode psychosis \u2013 A longitudinal assessment. Schizophr Res. 2017 Nov 1;189:117\u2013125. https:\/\/doi.org\/10.1016\/j.schres.2017.07.037","DOI":"10.1016\/j.schres.2017.07.037"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs. 2004 Oct;64(20):2291\u20132314. https:\/\/doi.org\/10.2165\/00003495-200464200-00003","DOI":"10.2165\/00003495-200464200-00003"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Yoshida K, Takeuchi H. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res. 2021 Mar 26;402:113098. https:\/\/doi.org\/10.1016\/j.bbr.2020.113098","DOI":"10.1016\/j.bbr.2020.113098"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Feb 23;71(9):14740. https:\/\/doi.org\/10.4088\/JCP.08m04307yel","DOI":"10.4088\/JCP.08m04307yel"},{"key":"ref11","unstructured":"Olose EO, Chukwujekwu CD, Busari CO, Igwe MN. Hyperprolactinemia in psychiatric patients taking antipsychotic medications: A longitudinal study in a tertiary hospital in South-South, Nigeria. Biol Med. 2021;13(9):100\u2013292."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Bonete Llacer JM, Martinez Hortelano A, Richart Albelda B. Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics. Int J Psychiatry Clin Pract. 2019 Jul 3;23(3):189\u2013193. https:\/\/doi.org\/10.1080\/13651501.2019.1576905","DOI":"10.1080\/13651501.2019.1576905"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Herceg M. Correlation between prolactin and symptom profile in acute admitted women with recurrent schizophrenia. Psychiatr Danub. 2020;32(3\u20134):367\u2013372. https:\/\/doi.org\/10.24869\/psyd.2020.367","DOI":"10.24869\/psyd.2020.367"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Wang ZM, Xiang YT, An FR, et al. Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. Perspect Psychiatr Care. 2014 Oct;50(4):257\u2013263. https:\/\/doi.org\/10.1111\/ppc.12050","DOI":"10.1111\/ppc.12050"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Delgado-Alvarado M, Tordesillas-Gutierrez D, Ayesa-Arriola R, et al. Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients. Arch Womens Ment Health. 2019 Jun;22(3):367\u2013373. https:\/\/doi.org\/10.1007\/s00737-018-0899-x","DOI":"10.1007\/s00737-018-0899-x"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Del Cacho N, Butjosa A, Vila-Badia R, et al. Prolactin levels in drug-na\u00efve first-episode nonaffective psychosis patients compared with healthy controls. Sex differences. Psychiatry Res. 2019 Jun 1;276:218\u2013222. https:\/\/doi.org\/10.1016\/j.psychres.2019.03.027","DOI":"10.1016\/j.psychres.2019.03.027"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wasnik V, Khess CR, Munda S, Bijali S. Serum prolactin level and its correlation with psychopathology in drug free\/drug naive schizophrenia a case control study. Asian J Psychiatry. 2019 Jan 1;39:1\u20135. https:\/\/doi.org\/10.1016\/j.ajp.2018.11.002","DOI":"10.1016\/j.ajp.2018.11.002"},{"key":"ref18","unstructured":"Tietz N. Clinical guide to laboratory test. 2nd ed. Philadelphia, PA: WB Saunders; 1992."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261","DOI":"10.1093\/schbul\/13.2.261"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Odinka PC, Ndukuba AC, Muomah RC, et al. Positive and negative symptoms of schizophrenia as correlates of help-seeking behaviour and the duration of untreated psychosis in South-East Nigeria. S Afr J Psychiatry. 2014;20(4):166. https:\/\/doi.org\/10.4102\/sajpsychiatry.v20i4.536","DOI":"10.7196\/sajp.536"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241\u2013247. https:\/\/doi.org\/10.1016\/S0920-9964(99)00130-9","DOI":"10.1016\/S0920-9964(99)00130-9"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Owie GO, Olotu SO, James BO. Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria. Trends Psychiatry Psychother. 2018 May 14;40(2):85\u201392. https:\/\/doi.org\/10.1590\/2237-6089-2017-0077","DOI":"10.1590\/2237-6089-2017-0077"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kelly DL, Wehring HJ, Earl AK, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: Presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry. 2013;13:214. https:\/\/doi.org\/10.1186\/1471-244X-13-214","DOI":"10.1186\/1471-244X-13-214"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Alosaimi FD, Fallata EO, Abalhassan M, et al. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int J Psychiatry Clin Pract. 2018 Oct 2;22(4):274\u2013281. https:\/\/doi.org\/10.1080\/13651501.2018.1425459","DOI":"10.1080\/13651501.2018.1425459"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kikuchi T, Iwamoto K, Sasada K, Aleksic B, Yoshida K, Ozaki N. Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):26\u201332. https:\/\/doi.org\/10.1016\/j.pnpbp.2011.11.016","DOI":"10.1016\/j.pnpbp.2011.11.016"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Retief M, Chiliza B, Phahladira L, Emsley R, Asmal L. Prolactin, flupenthixol decanoate and first episode schizophrenia\u2013clinical and laboratory correlates. Metab Brain Dis. 2019 Dec;34(6):1679\u20131687. https:\/\/doi.org\/10.1007\/s11011-019-00474-5","DOI":"10.1007\/s11011-019-00474-5"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004 Jan 1;65(1):57\u201361. https:\/\/doi.org\/10.4088\/JCP.v65n0109","DOI":"10.4088\/JCP.v65n0109"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychoties in schizophrenic patients. J Clin Psychiatry. 2005 Jun 1;66(6):761\u2013767. https:\/\/doi.org\/10.4088\/JCP.v66n0614","DOI":"10.4088\/JCP.v66n0614"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Stojkovic M, Radmanovic B, Jovanovic M, Janjic V, Muric N, Ristic DI. Risperidone induced hyperprolactinemia: From basic to clinical studies. Front Psychiatry. 2022;13:874705. https:\/\/doi.org\/10.3389\/fpsyt.2022.874705","DOI":"10.3389\/fpsyt.2022.874705"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: Mechanisms, consequences and management. Clin Endocrinol. 2011 Feb;74(2):141\u2013147. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03814.x","DOI":"10.1111\/j.1365-2265.2010.03814.x"}],"container-title":["South African Journal of Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/sajp.org.za\/index.php\/sajp\/article\/viewFile\/2133\/3233","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajp.org.za\/index.php\/sajp\/article\/viewFile\/2133\/3234","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajp.org.za\/index.php\/sajp\/article\/viewFile\/2133\/3235","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajp.org.za\/index.php\/sajp\/article\/viewFile\/2133\/3236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajp.org.za\/index.php\/sajp\/article\/view\/2133\/3236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:32Z","timestamp":1788866012000},"score":1,"resource":{"primary":{"URL":"https:\/\/sajp.org.za\/index.php\/sajp\/article\/view\/2133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":31,"journal-issue":{"issue":"0","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/sajpsychiatry.v30i0.2133","relation":{},"ISSN":["1608-9685","2078-6786"],"issn-type":[{"value":"1608-9685","type":"print"},{"value":"2078-6786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"article-number":"a2133"}}